Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
Open Access
- 16 October 2017
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (1) , 141-149
Abstract
Quality of life (QoL) is decreased in patients with Fabry disease (FD). To improve QoL, it is important to understand the influence of FD related characteristics, symptoms, and complications. In this retrospective cohort study we explored the effect of pain (measured by the Brief Pain Inventory), phenotype, treatment, and FD‐related complications on QoL. QoL data of Fabry patients as assessed by the EuroQol five dimension questionnaire (EQ‐5D) from two international centers of excellence were collected. The aim of this study was to evaluate the effect of sex, phenotype, age, different states of disease severity, pain, and ERT on EQ‐5D utilities. For 286 adult FD patients (mean age 42.5 years, 40% men, 60% classical phenotype) 2240 EQ‐5Ds were available. QoL is decreased in men as well as women with FD, especially in older men with a classical phenotype. At age 50, utility was lower in men with classical FD compared to those with non‐classical disease (β = −0.12, 95% CI: ‐0.23 – 0.01, p = 0.037) with further difference in the years thereafter. Cardiovascular complications, stroke or transient ischemic attacks, multiple FD‐related complications and pain were also associated with decreased utilities. Overall, no change in utility was seen in patients on ERT over a mean follow‐up of 6.1 years. FD leads to a decreased QoL compared to the general population. Disease complications and pain both negatively influence QoL. Adequate assessment and treatment of pain as well as improved strategies to prevent disease complications are needed to improve QoL in the FD population.Keywords
Funding Information
- University of Amsterdam
This publication has 42 references indexed in Scilit:
- Alcohol-induced severe acute pancreatitis followed by hemolytic uremic syndrome managed with continuous renal replacement therapyBMC Nephrology, 2014
- Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brainOrphanet Journal of Rare Diseases, 2013
- Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography–Tandem Mass SpectrometryClinical Chemistry, 2013
- Cost-effectiveness of enzyme replacement therapy for Fabry diseaseOrphanet Journal of Rare Diseases, 2013
- MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencingOrphanet Journal of Rare Diseases, 2013
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- The Placebo Effect: Illness and Interpersonal HealingPerspectives in Biology and Medicine, 2009
- The Dutch tariff: results and arguments for an effective design for national EQ‐5D valuation studiesHealth Economics, 2006
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990